Summary & Overview
CPT 80360: Methylphenidate Detection and Quantification
CPT code 80360 represents laboratory testing to detect or quantify methylphenidate, a central nervous system stimulant commonly prescribed for attention deficit disorders. Nationally, this code matters for clinical toxicology workflows, medication monitoring programs, compliance with controlled substance policies, and laboratory billing practices. The test supports clinical decision-making by confirming prescription adherence, evaluating potential misuse, or monitoring therapy.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of how 80360 is used in practice, the typical clinical contexts and sites of service, and common billing considerations tied to laboratory toxicology services. The publication also summarizes benchmark topics relevant to payers and laboratories, highlights policy and billing updates when applicable, and situates the test within clinical pathways for attention deficit disorder management.
This overview is written for a national audience interested in coding, reimbursement, and clinical use of methylphenidate testing in laboratory settings. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 80360 describes a laboratory test in which the analyst measures the amount of, or detects the presence of, methylphenidate — a central nervous system stimulant used to treat attention deficit disorders — in a patient specimen.
-
Service type: Clinical laboratory toxicology testing for a prescription stimulant
-
Typical site of service: Clinical laboratory, hospital laboratory, or outpatient specimen collection site
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A primary care physician or outpatient behavioral health clinic orders a specimen drug test to detect or quantify methylphenidate in a patient with a history of attention-deficit/hyperactivity disorder (ADHD) who is receiving stimulant therapy or is being evaluated for diversion, adherence, or unreported stimulant use. Typical workflow: the clinician documents the indication (e.g., medication monitoring, suspected diversion, impairment evaluation), obtains informed consent, collects a urine or serum specimen per laboratory instructions, and sends the specimen to a clinical laboratory. The laboratory analyst performs the analytic assay to detect or measure methylphenidate and reports presence/absence or concentration to the ordering clinician. Typical sites of service include outpatient clinics, urgent care centers, employee health/impaired-safety programs, forensic or occupational testing sites, and clinical laboratories. A common patient scenario: a 16-year-old with ADHD on prescribed methylphenidate presents for routine follow-up; the clinician orders a urine drug test to confirm therapeutic use and adherence prior to school medication administration, or a prescriber requests analysis after suspecting nonadherence or illicit stimulant exposure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the service |